APA (7th ed.) Citation

NW, C., A, A., FC, I., A, H., CL, A., G, A., . . . ND, J. (2020). Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Annals of oncology : official journal of the European Society for Medical Oncology, 31(3), 442. https://doi.org/10.1016/j.annonc.2020.01.002

Chicago Style (17th ed.) Citation

NW, Clarke, et al. "Corrigendum to Addition of Docetaxel to Hormonal Therapy in Low- and High-burden Metastatic Hormone Sensitive Prostate Cancer: Long-term Survival Results from the STAMPEDE Trial: Ann Oncol 2019; 30: 1992-2003." Annals of Oncology : Official Journal of the European Society for Medical Oncology 31, no. 3 (2020): 442. https://doi.org/10.1016/j.annonc.2020.01.002.

MLA (9th ed.) Citation

NW, Clarke, et al. "Corrigendum to Addition of Docetaxel to Hormonal Therapy in Low- and High-burden Metastatic Hormone Sensitive Prostate Cancer: Long-term Survival Results from the STAMPEDE Trial: Ann Oncol 2019; 30: 1992-2003." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 31, no. 3, 2020, p. 442, https://doi.org/10.1016/j.annonc.2020.01.002.